AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results from the Phase III WAYPOINT study for Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The drug, a thymic stromal lymphopoietin (TSLP)-targeted monoclonal antibody (mAb) co-developed with US firm Amgen (NASDAQ: AMGN), successfully met its co-primary endpoints by significantly reducing nasal polyps and alleviating nasal congestion compared to placebo.
Tezepelumab’s Mechanism of Action
As a first-in-class medication, tezepelumab has the ability to bind to TSLP and inhibit its interaction with receptor complexes. This action prevents TSLP from activating immune cells and releasing pro-inflammatory cytokines, which are responsible for inflammation in conditions such as CRSwNP.
Broad Application of Tezepelumab
Beyond its application in CRSwNP, tezepelumab is also under assessment for other respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). The positive results from the WAYPOINT study contribute to the growing body of evidence supporting the potential of tezepelumab as a treatment across a range of inflammatory diseases.-Fineline Info & Tech
Leave a Reply